文献速递泌尿男性生殖肿瘤

前列腺切除术后大分割放疗对比常规分割放疗对泌尿生殖系统和胃肠道症状的非劣效性:NRG-GU003 3期随机临床试验

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2024-01-01

NRG-GU003 3期随机试验纳入296例前列腺切除术后患者,随机接受大分割放疗(62.5 Gy/25次)或常规分割放疗(66.6 Gy/37次)。2年时大分割放疗在患者报告的泌尿生殖系统和胃肠道症状变化评分上非劣效于常规分割放疗;放疗结束时大分割组胃肠道症状更明显,但6个月内两组均恢复至基线水平。

要点

  • 大分割放疗(62.5 Gy/25次)在2年泌尿生殖系统和胃肠道症状评分上非劣效于常规分割放疗
  • 放疗结束时大分割组胃肠道症状评分变化更差,但6个月时两组均恢复至基线
  • 两组2年生化失败率无显著差异(12% vs 8%,P=.28)

核心结论

  • 放疗结束时大分割放疗组患者报告的胃肠道毒性反应大于常规分割放疗组,但两组均在6个月内恢复至基线水平。
  • 2年时大分割放疗在患者报告的泌尿生殖系统或胃肠道毒性反应方面非劣效于常规分割放疗。
  • 大分割放疗是前列腺切除术后放疗患者新的可接受实践标准。

研究设计与样本

  • 3期随机临床试验,于美国和加拿大93个学术、社区和三级医疗站点开展。
  • 2017年6月至2018年7月共随机分配296例前列腺切除术后患者,中位(范围)年龄65(44-81)岁,100%男性。
  • 患者随机接受62.5 Gy分25次(大分割放疗组,144例)或66.6 Gy分37次(常规分割放疗组,152例)。
  • 入组条件为前列腺切除术后可检测到前列腺特异性抗原(≥0.1 ng/mL)且为pT2/3pNX/0期疾病,或前列腺特异性抗原不可检测(<0.1 ng/mL)但为pT3期疾病或pT2期疾病伴手术切缘阳性。

主要发现

  • 放疗结束时大分割组和常规分割组胃肠道症状评分平均变化分别为-15.52(SD 18.43)和-7.06(SD 12.78),差异有统计学意义(P<.001),但6个月和12个月时该差异已消失。
  • 24个月时泌尿生殖系统症状评分平均变化大分割组为-5.01(SD 15.10),常规分割组为-4.07(SD 14.67),非劣效界值-5,拒绝劣效性原假设(P=.005)。
  • 24个月时胃肠道症状评分平均变化大分割组为-4.17(SD 10.97),常规分割组为-1.41(SD 8.32),非劣效界值-6,拒绝劣效性原假设(P=.02)。
  • 中位随访(删失患者)2.1年,大分割组与常规分割组生化失败(定义为PSA≥0.4 ng/mL且上升)无差异,2年发生率12% vs 8%(P=.28)。

临床怎么用

  • 作者认为大分割放疗是前列腺切除术后放疗患者新的可接受实践标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: No prior trial has compared hypofractionated postprostatectomy radiotherapy (HYPORT) to conventionally fractionated postprostatectomy (COPORT) in patients primarily treated with prostatectomy. OBJECTIVE: To determine if HYPORT is noninferior to COPORT for patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms at 2 years. DESIGN, SETTING, AND PARTICIPANTS: In this phase 3 randomized clinical trial, patients with a detectable prostate-specific antigen (PSA; ≥0.1 ng/mL) postprostatectomy with pT2/3pNX/0 disease or an undetectable PSA (<0.1 ng/mL) with either pT3 disease or pT2 disease with a positive surgical margin were recruited from 93 academic, community-based, and tertiary medical sites in the US and Canada. Between June 2017 and July 2018, a total of 296 patients were randomized. Data were analyzed in December 2020, with additional analyses occurring after as needed. INTERVENTION: Patients were randomized to receive 62.5 Gy in 25 fractions (HYPORT) or 66.6 Gy in 37 fractions (COPORT). MAIN OUTCOMES AND MEASURES: The coprimary end points were the 2-year change in score from baseline for the bowel and urinary domains of the Expanded Prostate Cancer Composite Index questionnaire. Secondary objectives were to compare between arms freedom from biochemical failure, time to progression, local failure, regional failure, salvage therapy, distant metastasis, prostate cancer-specific survival, overall survival, and adverse events. RESULTS: Of the 296 patients randomized (median [range] age, 65 [44-81] years; 100% male), 144 received HYPORT and 152 received COPORT. At the end of RT, the mean GU change scores among those in the HYPORT and COPORT arms were neither clinically significant nor different in statistical significance and remained so at 6 and 12 months. The mean (SD) GI change scores for HYPORT and COPORT were both clinically significant and different in statistical significance at the end of RT (-15.52 [18.43] and -7.06 [12.78], respectively; P < .001). However, the clinically and statistically significant differences in HYPORT and COPORT mean GI change scores were resolved at 6 and 12 months. The 24-month differences in mean GU and GI change scores for HYPORT were noninferior to COPORT using noninferiority margins of -5 and -6, respectively, rejecting the null hypothesis of inferiority (mean [SD] GU score: HYPORT, -5.01 [15.10] and COPORT, -4.07 [14.67]; P = .005; mean [SD] GI score: HYPORT, -4.17 [10.97] and COPORT, -1.41 [8.32]; P = .02). With a median follow-up for censored patients of 2.1 years, there was no difference between HYPORT vs COPORT for biochemical failure, defined as a PSA of 0.4 ng/mL or higher and rising (2-year rate, 12% vs 8%; P = .28). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, HYPORT was associated with greater patient-reported GI toxic effects compared with COPORT at the completion of RT, but both groups recovered to baseline levels within 6 months. At 2 years, HYPORT was noninferior to COPORT in terms of patient-reported GU or GI toxic effects. HYPORT is a new acceptable practice standard for patients receiving postprostatectomy radiotherapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03274687.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Buyyounouski MK, Pugh SL, Chen RC, et al. Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 38483412. doi:10.1001/jamaoncol.2023.7291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。